Bavdegalutamide (ARV-110) is a PROTAC protein degrader for prostate cancer. Bavdegalutamide promotes ubiquitination and degradation of androgen receptor (AR).
| Product Name | Bavdegalutamide |
| Synonyms | ARV-110 |
| CAS Number | 2222112-77-6 |
| Related CAS | |
| Molecular Formula | C41H43ClFN9O6 |
| Molecular Weight | 812.3 |
| SMILES | FC1=CC2=C(C=C1N1CCN(CC3CCN(CC3)C3=NN=C(C=C3)C(=O)N[C@H]3CC[C@@H](CC3)OC3=CC=C(C#N)C(Cl)=C3)CC1)C(=O)N(C1CCC(=O)NC1=O)C2=O |
| Purity (HPLC) | >= 95% |
| Physical Appearance | White solid |
| Solubility | DMSO, DMF |
| Shipping Conditions | Room Temperature |
| Storage Conditions | Refrigerated |
| Shelf Life | 12 months after the date of delivery |
| Regulatory Statement | For Research Use Only |
References
Taavi Neklesa, Lawrence B. Snyder, Ryan R. Willard, Nicholas Vitale, Kanak Raina, Jennifer Pizzano, Deborah Gordon, Mark Bookbinder, Jennifer Macaluso, Hanqing Dong, Zheng Liu, Caterina Ferraro, Gan Wang, Jing Wang, Craig M. Crews, John Houston, Andrew P. Crew, Ian Taylor. ARV-110: An androgen receptor PROTAC degrader for prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5236. https://doi.org/10.1158/1538-7445.AM2018-5236
Documents
Datasheet COA MSDS
Citations
If you know of a paper that uses this product from Tenova Pharma, please let us know.